scFv(CD20)-CD28-CD3zeta CAR-T Lentivirus

CAR-T, short for Chimeric Antigen Receptor T-Cell Immunotherapy, is a treatment method that uses genetic engineering to artificially modify a patient''s T cells. Tumor-specific CAR-T cells are then cultured in vitro and then infused back into the patient to attack cancer cells.

CARs are composed of three main domains: an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain. The extracellular antigen-binding domain consists of a single-chain variable fragment (scFv) of a monoclonal antibody that recognizes and binds to the antigen, and a hinge region that acts as a linker. The transmembrane domain facilitates CAR expression on the T cell surface. The intracellular signaling domain, comprised of a signal transduction domain and a costimulatory domain (first-generation CARs lack a costimulatory domain), is crucial for T cell activation. The single-chain variable fragment (scFv) serves as the antigen-binding domain, connecting the transmembrane domain to the intracellular signaling domain. It recognizes and binds to antigens presented by cancer cells, then transmits the extracellular antigen-binding signal to the CAR-T cell, initiating the activation of the downstream signaling cascade.